Program
entecavir
Also written as “Entecavir”, “Entecavir (ETV)” and “Entecavir + Tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 240 open or running | phase 4since Aug 29, 2006 | May 4, 2002 | none ahead |
| Hoffmann-La Roche | 40 open or running | phase 4since Jan 30, 2008 | Jan 30, 2008 | none ahead |
| Ascentage Pharma Group International | 11 open or running | phase 2since Sep 24, 2020 | Sep 24, 2020 | none ahead |
| aucta-pharmaceuticals-inc | 10 open or running | phase 1since Jul 27, 2017 | Jul 27, 2017 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 4since Jul 26, 2015 | Jul 26, 2015 | none ahead |
| Sino Biopharmaceutical | 10 open or running | no phasesince Jan 22, 2019 | Jan 22, 2019 | none ahead |
Also a collaborator on its studies: icon-clinical-research and cpr-pharma-services-pty-ltd-australia.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since May 4, 2002.
- Sep 8, 2009Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT00975091 · 600 enrolled
- Sep 29, 2009Phase 4 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT00986778
- Nov 24, 20092 phase 2 studies in Hepatitis B, ChronicBristol-Myers Squibb · NCT01020565, NCT01022801
- Dec 17, 20092 phase 2 studies in Hepatitis B, ChronicBristol-Myers Squibb · NCT01037166, NCT01037062
- Feb 3, 2010Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT01063036 · 144 enrolled · France, Germany, Italy and more
- Mar 2, 2010Phase 3 study in Hepatitis B, ChronicBristol-Myers Squibb · NCT01079806 · 180 enrolled · United States, Argentina, Belgium and more
- Aug 10, 2010Phase 4 study in Hepatitis B, ChronicHoffmann-La Roche · NCT01179594
- Sep 16, 2011Phase 2 study in Hepatitis BBristol-Myers Squibb · NCT01438424 · 1,053 enrolled
- Oct 2, 2014Phase 3 study in Pediatric Immuno-Tolerant Chronic Hepatitis BHoffmann-La Roche · NCT02263079 · 62 enrolled · United States, Australia, Belgium and more
- Jul 26, 2015Hanmi Pharmaceutical's first study: phase 4 study in Hepatitis B, ChronicNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT02523547 · 134 enrolled · Korea, Republic of
- Mar 14, 2017Phase 1 study in Hepatitis BBristol-Myers Squibb · NCT03083821 · 6 enrolled · Japan
- Jul 27, 2017aucta-pharmaceuticals-inc's first study: phase 1 study in HBVNew to aucta-pharmaceuticals-incaucta-pharmaceuticals-inc · NCT03239353 · 40 enrolled · Australia
- Jan 22, 2019Sino Biopharmaceutical's first study: no phase study in Hepatitis B, ChronicNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03847246 · 26 enrolled · China
- Sep 24, 2020Ascentage Pharma Group International's first study: phase 2 study in Hepatitis BNew to Ascentage Pharma Group InternationalAscentage Pharma Group International · NCT04568265 · 122 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA polymerase/reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04568265Hepatitis B · China | 2 | Recruiting | Ascentage Pharma Group International | Oct 31, 2022 | 122 |
| NCT03847246Hepatitis B, Chronic · China | – | Completed | Sino Biopharmaceutical | Dec 28, 2018 | 26 |
| NCT03239353HBV · Australia | 1 | Completed | aucta-pharmaceuticals-inc | May 29, 2018 | 40 |
| NCT03083821Hepatitis B · Japan | 1 | Completed | Bristol-Myers Squibb | Dec 19, 2017 | 6 |
| NCT02523547Hepatitis B, Chronic · Korea, Republic of | 4 | UNKNOWN | Hanmi Pharmaceutical | Feb 2017 | 134 |
| NCT02263079Pediatric Immuno-Tolerant Chronic Hepatitis B · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Jan 29, 2020 | 62 |
| NCT01438424Hepatitis B | 2 | Completed | Bristol-Myers Squibb | Dec 2009 | 1,053 |
| NCT01179594Hepatitis B, Chronic | 4 | Withdrawn | Hoffmann-La Roche | Nov 2014 | 0 |
| NCT01079806Hepatitis B, Chronic · United States, Argentina, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Mar 31, 2013 | 180 |
| NCT01063036Hepatitis B, Chronic · France, Germany, Italy and more | 3 | Completed | Bristol-Myers Squibb | Nov 2012 | 144 |
| NCT01037166Hepatitis B, Chronic · Japan | 2 | Completed | Bristol-Myers Squibb | Feb 2005 | 84 |
| NCT01037062Hepatitis B, Chronic · Japan | 2 | Completed | Bristol-Myers Squibb | Dec 2006 | 282 |
| NCT01022801Hepatitis B, Chronic | 2 | Completed | Bristol-Myers Squibb | Mar 2005 | 120 |
| NCT01020565Hepatitis B, Chronic | 2 | Completed | Bristol-Myers Squibb | Feb 2005 | 60 |
| NCT00986778Hepatitis B, Chronic | 4 | Withdrawn | Bristol-Myers Squibb | Dec 2012 | 0 |
| NCT00975091Hepatitis B, Chronic | 3 | Completed | Bristol-Myers Squibb | Aug 2007 | 600 |
| NCT00922207Hepatitis B, Chronic · Taiwan | 4 | Completed | Hoffmann-La Roche | Sep 29, 2014 | 280 |
| NCT00718887Hepatitis B, Chronic · China | 4 | Completed | Bristol-Myers Squibb | Dec 2009 | 228 |
| NCT00614471Hepatitis B, Chronic · China, Hong Kong | 4 | Completed | Hoffmann-La Roche | Oct 2009 | 219 |
| NCT00605384Hepatitis B, Chronic · United States, Belgium, Germany and more | 3 | Terminated | Bristol-Myers Squibb | Feb 2009 | 4 |
| NCT00423891Hepatitis B, Chronic · United States, Argentina, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Aug 31, 2013 | 64 |
| NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jan 2011 | 629 |
| NCT00410072Hepatitis B, Chronic · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Oct 2010 | 669 |
| NCT00395018Hepatitis B, Chronic · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Mar 2011 | 109 |
| NCT00393484Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Bristol-Myers Squibb | Jan 2009 | 122 |
| NCT00371150Hepatitis B · United States, Brazil, Mexico and more | 4 | Completed | Bristol-Myers Squibb | Mar 2011 | 131 |
| NCT00096785Hepatitis B · United States, Canada, Hong Kong and more | 3 | Completed | Bristol-Myers Squibb | Jan 2006 | 69 |
| NCT00065507Hepatitis B · United States, Brazil, Canada and more | 3 | Completed | Bristol-Myers Squibb | Oct 2008 | 195 |
| NCT00051038Hepatitis B · United States | 3 | Completed | Bristol-Myers Squibb | Oct 2005 | |
| NCT00036608Hepatitis B, Chronic · United States | 3 | Completed | Bristol-Myers Squibb | Feb 2005 | |
| NCT00035789Hepatitis B, Chronic · United States | 3 | Completed | Bristol-Myers Squibb | May 2005 | |
| NCT00035633Hepatitis B, Chronic · United States | 3 | Completed | Bristol-Myers Squibb | Feb 2005 |
How it is read
Names in the registry
- “Entecavir”, 28 entries
- “entecavir”, 4 entries
- “Entecavir (ETV)”, 2 entries
- “Entecavir + Tenofovir”, 2 entries
- “P1101 + Nivolumab + Entecavir”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 34 studies
- Hepatitis B, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.